VJHemOnc is committed to improving our service to you

ESH AL 2020 | AML: new targeted inhibitors as single agents?

VJHemOnc is committed to improving our service to you

Christoph Röllig

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the use of new targeted inhibitors as single agents or in combination with standard intensive or novel non-intensive treatment approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter